

Navdeep Rinwa,
Joint Secretary,
Department of Pharmaceuticals



Rajiv Wadhawan,
Director,
Ministry of Health
& Family Welfare

F.No.X.11035/110/2021-DRS(pt)

Date : 11th May, 2021

Dear Sir/Madam,

As informed earlier, Tocilizumab is sourced only through imports from a pharmaceutical company Hoffman La Roche, by Roche India and is marketed in India by Cipla Ltd. While the sale of Tocilizumab to various States/UTs is being undertaken directly by Cipla Ltd. , the Central Govt is making all efforts to ensure that the drug is available across the country. Towards this end, an allocation of 9900 vials (200mg) of Tocilizumab was made for States/UTs along with Central health institutions vide our DO letter dated 30th April, 2021. The Ministry of Health and Family Welfare vide letter No. A-45013/45/2020-HPE-(37) dated 10th May, 2021 has also allocated 50024 vials (80mg) received through donation among States and Central health institutions.

2. Now, as the second lot of Tocilizumab imported for commercial sales has arrived in India on 10th May, 2021, please find enclosed a further allocation of 45000 vials of Tocilizumab (80 mg strength). The allocated vials are being placed at the disposal of the Health Department of State Governments/UTs for subsequent allocation to both the Government as well as the Private Hospitals of the concerned State. No separate quantity of Tocilizumab is being allocated directly to the private hospitals located in the States. **The Private Hospitals in States should be informed by the State Governments that they have to contact the Health Department of their respective State to source the drug.**

3. 2500 vials of central allocation will be at the disposal of the Ministry of Health and Family Welfare for further allocation to Health Institutions under MoHFW. Such institutions may approach Mr Niambuj Sharan, Economic Adviser, MoHFW (nilambuj.sharan@nic.in) for their requirement of Tocilizumab.

4. Another 2500 vials of central allocation will be at the disposal of the Department of Pharmaceuticals for further allocation to Health Institutions under Ministries other than MoHFW. Such Institutions may contact Mr Alok Malviya, Director on attachment in DoP (alok.malviya@nic.in) for their requirement of Tocilizumab.

5. The distribution is being done to States looking only at the recent active case load in the States. The States are requested to prevent hoarding/black marketing and also ensure that the drug is used

judiciously strictly according to the treatment protocol advised in the clinical guidance issued by Joint Monitoring Group of MoHFW.

6. The State Governments are requested to widely publicize the mechanism put in place in their respective state of obtaining the allocated vials by the needy patients, Private Hospitals and Government hospitals. The State governments are also requested to keep a record of the subsequent distribution of the allocated quantity and make the information available at the request of the Govt. of India. State Governments are also requested to nominate a nodal officer for management of the allocated stocks and convey the details of the nodal officer (Name, Designation, Mobile, Email id) to the monitoring cell set up under Chairperson, National Pharmaceutical Pricing Authority at monitoring-nppa@gov.in, if not earlier conveyed.

Yours sincerely,



(Navdeep Rinwa)



(Rajiv Wadhawan)

Encl: a/a.

To,

1. Additional Chief Secretary/Principal Secretary/Secretary Health of States/UTs.
2. Shri Rajesh Bhushan Secretary, Department of Health & Family Welfare, Government of India
3. Ms S.Aparna, Secretary Department of Pharmaceuticals , Government of India
4. All Secretaries to Govt. of India.

Copy for Information to-

1. Shri Ajay Bhalla, Secretary, Ministry of Home Affairs
2. Ms Shubhra Singh, Chairperson NPPA
3. Shri Alkesh Sharma, Additional Secretary, Cabinet Secretariat
4. Ms P. Amudha, Additional Secretary, PMO
5. Shri Rohit Yadav, Joint Secretary, PMO
6. Dr V G Somani, DCGI
7. Mr Niambuj Sharan, Economic Adviser, MoHFW
8. Mr Alok Malviya, Director on attachment in DoP

Copy to -

Shri Jortin George, Cipla Ltd., Mumbai- To contact the Additional Chief Secretary/Principal Secretary/Secretary Health of States/UTs and inform them of the details of the depots at which the stocks will be placed.

Allocation of Tocilizumab to States

S No.	State/UT	Total No of Vials (80 mg)
1	Andaman and Nicobar Islands	20
2	Andhra Pradesh	2040
3	Arunachal Pradesh	20
4	Assam	420
5	Bihar	1130
6	Chandigarh	95
7	Chhattisgarh	1350
8	Dadra and Nagar Haveli and Daman and Diu	20
9	Delhi	920
10	Goa	350
11	Gujarat	1465
12	Haryana	1220
13	Himachal Pradesh	370
14	Jammu and Kashmir	530
15	Jharkhand	625
16	Karnataka	6150
17	Kerala	4500
18	Ladakh	20
19	Lakshadweep	20
20	Madhya Pradesh	1190
21	Maharashtra	6380
22	Manipur	50
23	Meghalaya	35
24	Mizoram	20
25	Nagaland	30
26	Odisha	915
27	Puducherry	155
28	Punjab	815
29	Rajasthan	2185
30	Sikkim	30
31	Tamil Nadu	1640
32	Telangana	675
33	Tripura	30
34	Uttarakhand	800
35	Uttar Pradesh	2420
36	West Bengal	1365
Sub Total		40000
37	Central health institutions under MoHFW	2500
38	DoP / Other Central health institutions	2500
Total		45000